J B Chemicals & Pharmaceuticals Ltd share Price

JB Chemicals and Pharmaceuticals Ltd is a major player in the Indian pharmaceutical industry. It manufactures bulk drugs, chemicals, APIs, and a range of pharmaceutical products. It has five manufacturing facilities in Belapur, Thane, Ankleshwar, Panoli, and Daman. The majority of the company’s sales come from products such as Metrogyl, Rantac, and cardiac care medicines. The company also manufactures products for a wide range of therapeutic categories like gastroenterology, dermatology, hypertension, pharmacovigilance, and nicotine replacement therapy. Incorporated in 1976 in Maharashtra, JB Chemicals and Pharmaceuticals Ltd exports to 40 countries across the globe.

The company is listed on the Bombay Stock Exchange with code 506943 and the National Stock Exchange with the symbol JBCHEPHARM. On November 22, 2022, JB Chemicals and Pharmaceuticals Ltd had a market capitalisation of Rs 16,131 crore.

On November 22, 2022, JB Chemicals and Pharmaceuticals Ltd share price closed at Rs 2,043.95 per share, down by 2.01% from the open price of Rs 2,089.40. JB Chemicals and Pharmaceuticals Ltd’s share prices have increased by 430.04% over the past three years and 23.62% in the past 12 months. On November 22, 2022, the share’s 52-week high was Rs 2,150, and the 52-week low was Rs 1,342.20. 

The company earned Rs 809 crore in revenue in the September 2022 quarter. It has been the best quarter of the year for the company. It made a profit of Rs 111 crore, which is 11% higher than its profit in the September 2021 quarter.

Promoters hold 53.96% of the company’s shares, retail and others have a 19.31% stake, and 15.40% of the shares are held by mutual funds.

Nikhil Chopra is the company’s CEO and the whole-time director, Dilip Singh Rathore is the president of India business, Kunal Khanna is the president of operations, Lakshay Kataria is the CFO, Bhushan Sachdev is the vice president of the supply chain department, and Bharat Dhanani is the vice president of operations.

Disclaimer: ICICI Securities Ltd. (I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is a Member of National Stock Exchange of India Ltd (Member Code: 07730), BSE Ltd (Member Code: 103) and Member of Multi Commodity Exchange of India Ltd.(Member Code:  56250) and having SEBI registration no. INZ000183631. Name of the Compliance officer (broking): Ms. Mamta Shetty, Contact number: 022-40701022, E-mail address: complianceofficer@icicisecurities.com. Investments in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. Such representations are not indicative of future results. The securities quoted are exemplary and are not recommendatory. Investors should consult their financial advisers if in doubt about whether the product is suitable for them. The contents herein above are solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments or any other product. Investors should consult their financial advisers whether the product is suitable for them before taking any decision. The contents herein mentioned are solely for informational and educational purpose.